117 related articles for article (PubMed ID: 37844417)
1. The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells.
Aguilar-Chaparro MA; Rivera-Pineda SA; Hernández-Galdámez HV; Piña-Vázquez C; Villa-Treviño S
Stem Cell Res; 2023 Oct; 72():103222. PubMed ID: 37844417
[TBL] [Abstract][Full Text] [Related]
2. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.
Kakehashi A; Ishii N; Sugihara E; Gi M; Saya H; Wanibuchi H
Cancer Sci; 2016 May; 107(5):609-18. PubMed ID: 26882440
[TBL] [Abstract][Full Text] [Related]
3. CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line.
Asai R; Tsuchiya H; Amisaki M; Makimoto K; Takenaga A; Sakabe T; Hoi S; Koyama S; Shiota G
Cancer Med; 2019 Feb; 8(2):773-782. PubMed ID: 30636370
[TBL] [Abstract][Full Text] [Related]
4. NEAT1 is Required for the Expression of the Liver Cancer Stem Cell Marker CD44.
Koyama S; Tsuchiya H; Amisaki M; Sakaguchi H; Honjo S; Fujiwara Y; Shiota G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168951
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma.
Sakabe T; Azumi J; Umekita Y; Toriguchi K; Hatano E; Hirooka Y; Shiota G
Liver Int; 2017 Feb; 37(2):271-279. PubMed ID: 27473646
[TBL] [Abstract][Full Text] [Related]
6. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
Miwa T; Nagata T; Kojima H; Sekine S; Okumura T
Int J Oncol; 2017 Sep; 51(3):771-780. PubMed ID: 28677740
[TBL] [Abstract][Full Text] [Related]
7. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
[TBL] [Abstract][Full Text] [Related]
8. Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines.
Shu X; Liu H; Pan Y; Sun L; Yu L; Sun L; Yang Z; Ran Y
Mol Cell Biochem; 2019 Sep; 459(1-2):35-47. PubMed ID: 31073886
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CD44 Variant 9: A Novel Cancer Stem Cell Marker in Human Cholangiocarcinoma in Relation to Inflammation.
Suwannakul N; Ma N; Thanan R; Pinlaor S; Ungarreevittaya P; Midorikawa K; Hiraku Y; Oikawa S; Kawanishi S; Murata M
Mediators Inflamm; 2018; 2018():4867234. PubMed ID: 30402042
[TBL] [Abstract][Full Text] [Related]
10. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
11. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori-Infected CAPZA1-Overexpressing Cells.
Tsugawa H; Kato C; Mori H; Matsuzaki J; Kameyama K; Saya H; Hatakeyama M; Suematsu M; Suzuki H
Cell Mol Gastroenterol Hepatol; 2019; 8(3):319-334. PubMed ID: 31146068
[TBL] [Abstract][Full Text] [Related]
12. CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.
Taniguchi D; Saeki H; Nakashima Y; Kudou K; Nakanishi R; Kubo N; Ando K; Oki E; Oda Y; Maehara Y
Cancer Med; 2018 Dec; 7(12):6258-6268. PubMed ID: 30474922
[TBL] [Abstract][Full Text] [Related]
13. Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines.
Dinger TF; Chen O; Dittfeld C; Hetze L; Hüther M; Wondrak M; Löck S; Eicheler W; Breier G; Kunz-Schughart LA
Theranostics; 2020; 10(17):7599-7621. PubMed ID: 32685007
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
16. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer.
Leng Z; Xia Q; Chen J; Li Y; Xu J; Zhao E; Zheng H; Ai W; Dong J
Cell Physiol Biochem; 2018; 46(2):860-872. PubMed ID: 29627827
[TBL] [Abstract][Full Text] [Related]
17. FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells.
Lin B; Chen T; Zhang Q; Lu X; Zheng Z; Ding J; Liu J; Yang Z; Geng L; Wu L; Zhou L; Zheng S
Oncotarget; 2016 Nov; 7(47):77495-77507. PubMed ID: 27769048
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
19. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
20. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M
BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
